The results of the next series of experiments on the study of efficiency of prophylactic and medical application of new BAS — magnesium-oxyethylyndiphosphonategermanate (MIGU-6 or germacord) at experimental myocardial dystrophy are given in the article. It is established that at the peak of development of modeling myocardial dystrophy in rats (7th day) the substantial reduction of total level of adenylate nucleotides in cardiac muscle’s mitochondria was observed, that brought to discorrelation of certain fractions. Germacord prophylactic introduction substantially prevented these changes. At germacord medical introduction, regardless of the dose entered at the peak of the pathology development, the studied indices were restored up to the initial level of control animals already on the 5th day, while at untreated myocardial dystrophy — only on the 14th day. These data correlate with the results obtained before on the study of the tissue respiration, oxidizing phosphorylation and their coupling. Normalization of one of important links of the cardiac activity power supply underlines positive properties of a new compound.
